
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is well-positioned to capitalize on the projected growth of the biosimilar market, anticipated to reach $100 billion by 2030, providing significant revenue opportunities through its expanded pharmacy benefit management capabilities. The company's ability to generate double-digit savings on GLP-1 medications for employer clients further enhances its value proposition in health insurance services. Additionally, the build-out of Evernorth is expected to provide economic resilience, offsetting potential earnings headwinds during economic downturns, thereby reinforcing a positive outlook on Cigna's financial performance.
Bears say
Cigna Group faces several fundamental risks that may negatively impact its financial outlook, including challenges in accurately pricing and managing healthcare cost trends and prolonged regulatory scrutiny of pharmacy benefit managers (PBMs). Additionally, there are concerns regarding slow biosimilar adoption and insufficient specialty drug penetration, which could hinder growth for its Evernorth segment, coupled with potential client losses due to market dynamics. The company's management also anticipates limited material client shifting and adoption of new business structures under ICHRA/CHOICE, indicating a risk of adverse effects on employee benefit offerings, further exacerbated by potential increases in unemployment affecting commercial membership.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares